Advertisement

The Role of Integrated Interventions in Psychosomatic Diseases

  • Massimo Biondi
  • Francesco Saverio Bersani
  • Massimo Pasquini
Chapter
Part of the Integrating Psychiatry and Primary Care book series (IPPC)

Abstract

Based on the evidence that there can be no health without mental health, psychosomatic medicine recognizes the complexity of the interface between psychiatry, lifestyle and medicine. At the clinical level, psychosomatic medicine integrates interdisciplinary evaluation and management involving diverse specialties including psychiatry, psychology, neurology, internal medicine, allergology, dermatology, rheumatology and endocrinology. At the research level, the fields of psychoneuroimmunology and psychoneuroendocrinology integrate findings from neuroscience, experimental psychology, physiology, genetics, pharmacology and molecular biology to understand the mechanistic underpinnings of psychosomatics. A clinical approach based on personalized and scientifically based integrated interventions, consistent with the bio-psycho-social model of medicine, is the best way to actually promote clinically significant physical and mental health improvements.

References

  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.Google Scholar
  2. 2.
    Biondi M, Bersani FS, Valentini M. The Italian edition of DSM-5Riv Psichiatr. 2014;49(2):57–60.PubMedGoogle Scholar
  3. 3.
    Levenson JL. Essentials of psychosomatic medicine. Arlington, VA: American Psychiatric Press; 2006.Google Scholar
  4. 4.
    Prince M, et al. No health without mental health. Lancet. 2007;370(9590):859–77.PubMedGoogle Scholar
  5. 5.
    Biondi M. Beyond the brain-mind dichotomy and toward a common organizing principle of pharmacological and psychological treatments. Psychother Psychosom. 1995;64(1):1–8.PubMedGoogle Scholar
  6. 6.
    World Health Organization. Mental health: new understanding, new hope. 2001.Google Scholar
  7. 7.
    Helzer JE, et al. Dimensional approaches in diagnostic classification. Refining the research agenda for DSM-V. Arlington, VA: American Psychiatric Association; 2008.Google Scholar
  8. 8.
    Biondi M, Pasquini M. Dimensional psychopharmacology in somatising patients. Adv Psychosom Med. 2015;34:24–35.PubMedGoogle Scholar
  9. 9.
    Biondi M, et al. Dimensional psychopathology of depression: detection of an ‘activation’ dimension in unipolar depressed outpatients. J Affect Disord. 2005;84(2–3):133–9.PubMedGoogle Scholar
  10. 10.
    Dazzi F, et al. Predictors of inpatient psychiatric admission in patients presenting to the emergency department: the role of dimensional assessment. Gen Hosp Psychiatry. 2015;37(6):587–94.PubMedGoogle Scholar
  11. 11.
    Pancheri P, et al. Validazione della scala per la valutazione rapida dimensionale “SVARAD”. Riv Psichiatr. 1999;34:84–93.Google Scholar
  12. 12.
    Pasquini M, et al. Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. Depress Anxiety. 2006;23(7):441–8.PubMedGoogle Scholar
  13. 13.
    Pasquini M, et al. Relevance of anger and irritability in outpatients with major depressive disorder. Psychopathology. 2004;37(4):155–60.PubMedGoogle Scholar
  14. 14.
    Pasquini M, et al. Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: an open study. Clin Pract Epidemiol Ment Health. 2007;3:3.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Pancheri P, et al. Costruzione della “SVARAD”, una scala per la valutazione rapida dimensionale. Riv Psichiatr. 1999;34:72–83.Google Scholar
  16. 16.
    McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 2000;886(1–2):172–89.PubMedGoogle Scholar
  17. 17.
    Olff M, et al. Changes in cortisol and DHEA plasma levels after psychotherapy for PTSD. Psychoneuroendocrinology. 2007;32(6):619–26.PubMedGoogle Scholar
  18. 18.
    Fischer S, Cleare AJ. Cortisol as a predictor of psychological therapy response in anxiety disorders-systematic review and meta-analysis. J Anxiety Disord. 2017;47:60–8.PubMedGoogle Scholar
  19. 19.
    Epel E, et al. Can meditation slow rate of cellular aging? Cognitive stress, mindfulness, and telomeres. Ann N Y Acad Sci. 2009;1172:34–53.PubMedPubMedCentralGoogle Scholar
  20. 20.
    O’Donovan A, et al. Stress appraisals and cellular aging: a key role for anticipatory threat in the relationship between psychological stress and telomere length. Brain Behav Immun. 2012;26(4):573–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Kessler TA. The cognitive appraisal of health scale: development of psychometric evaluation. Res Nurs Health. 1998;21(1):73–82.PubMedGoogle Scholar
  22. 22.
    Levine AB, Levine LM, Levine TB. Posttraumatic stress disorder and cardiometabolic disease. Cardiology. 2014;127(1):1–19.PubMedGoogle Scholar
  23. 23.
    Lazarus RS, Folkman S. Stress, appraisal, and coping. Berlin: Springer; 1984.Google Scholar
  24. 24.
    Bigatti SM, Steiner JL, Miller KD. Cognitive appraisals, coping and depressive symptoms in breast cancer patients. Stress Health. 2012;28(5):355–61.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Lin FY, Rong JR, Lee TY. Resilience among caregivers of children with chronic conditions: a concept analysis. J Multidiscip Healthc. 2013;6:323–33.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Harmell AL, et al. A review of the psychobiology of dementia caregiving: a focus on resilience factors. Curr Psychiatry Rep. 2011;13(3):219–24.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Schulz R, Beach SR. Caregiving as a risk factor for mortality: the caregiver health effects study. JAMA. 1999;282(23):2215–9.PubMedGoogle Scholar
  28. 28.
    McCombie AM, Mulder RT, Gearry RB. Psychotherapy for inflammatory bowel disease: a review and update. J Crohns Colitis. 2013;7(12):935–49.PubMedGoogle Scholar
  29. 29.
    Gearry RB, et al. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25(2):325–33.PubMedGoogle Scholar
  30. 30.
    Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3(7):521–33.Google Scholar
  31. 31.
    Nicholson RA. Chronic headache: the role of the psychologist. Curr Pain Headache Rep. 2010;14(1):47–54.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Lumley MA. Beyond cognitive-behavioral therapy for fibromyalgia: addressing stress by emotional exposure, processing, and resolution. Arthritis Res Ther. 2011;13(6):136.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Salviati M, et al. A brain centred view of psychiatric comorbidity in tinnitus: from otology to hodology. Neural Plast. 2014;2014:817852.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Salviati M, et al. Tinnitus: clinical experience of the psychosomatic connection. Neuropsychiatr Dis Treat. 2014;10:267–75.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Hanifin JM, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”. J Am Acad Dermatol. 2004;50(3):391–404.PubMedGoogle Scholar
  36. 36.
    Colom F. The evolution of psychoeducation for bipolar disorder: from lithium clinics to integrative psychoeducation. World Psychiatry. 2014;13(1):90–2.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Adams RJ. Improving health outcomes with better patient understanding and education. Risk Manag Healthc Policy. 2010;3:61–72.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Bersani FS, et al. Psychoeducational intervention focused on healthy living improves psychopathological severity and lifestyle quality in psychiatric patients: preliminary findings from a controlled study. J Ment Health. 2017;26(3):271–5.PubMedGoogle Scholar
  39. 39.
    Chochinov HM, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol. 2005;23(24):5520–5.Google Scholar
  40. 40.
    Costantini A, Levenson JA, Bersani FS. In: Wise TN, Biondi M, Costantini A, editors. The crisis of discovery—psychological and psychopathological reaction to the disease, in psycho-oncology. Washington, DC: American Psychiatric Association; 2013.Google Scholar
  41. 41.
    Blackburn EH. Telomere states and cell fates. Nature. 2000;408(6808):53–6.PubMedGoogle Scholar
  42. 42.
    Blackburn EH. Telomeres and telomerase: the means to the end (Nobel lecture). Angew Chem Int Ed Engl. 2010;49(41):7405–21.PubMedGoogle Scholar
  43. 43.
    Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006;12(10):1133–8.PubMedGoogle Scholar
  44. 44.
    Bersani FS, et al. Telomerase activation as a possible mechanism of action for psychopharmacological interventions. Drug Discov Today. 2015;20(11):1305–9.PubMedGoogle Scholar
  45. 45.
    Starkweather AR, et al. An integrative review of factors associated with telomere length and implications for biobehavioral research. Nurs Res. 2014;63(1):36–50.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Bersani FS, et al. Association of dimensional psychological health measures with telomere length in male war veterans. J Affect Disord. 2016;190:537–42.PubMedGoogle Scholar
  47. 47.
    Lindqvist D, et al. Psychiatric disorders and leukocyte telomere length: underlying mechanisms linking mental illness with cellular aging. Neurosci Biobehav Rev. 2015;55:333–64.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Martin-Ruiz C, et al. Telomere length predicts poststroke mortality, dementia, and cognitive decline. Ann Neurol. 2006;60(2):174–80.PubMedGoogle Scholar
  49. 49.
    Cawthon RM, et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361(9355):393–5.PubMedGoogle Scholar
  50. 50.
    Fitzpatrick AL, et al. Leukocyte telomere length and cardiovascular disease in the cardiovascular health study. Am J Epidemiol. 2007;165(1):14–21.PubMedGoogle Scholar
  51. 51.
    Gorbunova V, Seluanov A. Telomerase as a growth-promoting factor. Cell Cycle. 2003;2(6):534–7.PubMedGoogle Scholar
  52. 52.
    Saretzki G. Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress. Curr Pharm Des. 2014;20(41):6386–403.PubMedGoogle Scholar
  53. 53.
    Scheffler IE. Mitochondria make a come back. Adv Drug Deliv Rev. 2001;49(1–2):3–26.PubMedGoogle Scholar
  54. 54.
    Johannsen DL, Ravussin E. The role of mitochondria in health and disease. Curr Opin Pharmacol. 2009;9(6):780–6.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Kasahara A, Scorrano L. Mitochondria: from cell death executioners to regulators of cell differentiation. Trends Cell Biol. 2014;24(12):761–70.PubMedGoogle Scholar
  56. 56.
    Campbell CT, Kolesar JE, Kaufman BA. Mitochondrial transcription factor a regulates mitochondrial transcription initiation, DNA packaging, and genome copy number. Biochim Biophys Acta. 2012;1819(9–10):921–9.PubMedGoogle Scholar
  57. 57.
    Clay Montier LL, Deng JJ, Bai Y. Number matters: control of mammalian mitochondrial DNA copy number. J Genet Genomics. 2009;36(3):125–31.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Bersani FS, et al. Mitochondrial DNA copy number is reduced in male combat veterans with PTSD. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:10–7.Google Scholar
  59. 59.
    Lee HC, Wei YH. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int J Biochem Cell Biol. 2005;37(4):822–34.PubMedGoogle Scholar
  60. 60.
    Moyes C, Battersby B. Regulation of muscle mitochondrial design. J Exp Biol. 1998;201(3):299–307.PubMedGoogle Scholar
  61. 61.
    Laderman KA, et al. Aging-dependent functional alterations of mitochondrial DNA (mtDNA) from human fibroblasts transferred into mtDNA-less cells. J Biol Chem. 1996;271(27):15891–7.PubMedGoogle Scholar
  62. 62.
    Bratic A, Larsson NG. The role of mitochondria in aging. J Clin Invest. 2013;123(3):951–7.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Blokhin A, et al. Variations in mitochondrial DNA copy numbers in MS brains. J Mol Neurosci. 2008;35(3):283–7.PubMedGoogle Scholar
  64. 64.
    Choi YS, Kim S, Pak YK. Mitochondrial transcription factor A (mtTFA) and diabetes. Diabetes Res Clin Pract. 2001;54(Suppl 2):S3–9.PubMedGoogle Scholar
  65. 65.
    Kim JH, Im JA, Lee DC. The relationship between leukocyte mitochondrial DNA contents and metabolic syndrome in postmenopausal women. Menopause. 2012;19(5):582–7.PubMedGoogle Scholar
  66. 66.
    Lee HK, et al. Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1998;42(3):161–7.PubMedGoogle Scholar
  67. 67.
    Macmillan CJ, Shoubridge EA. Mitochondrial DNA depletion: prevalence in a pediatric population referred for neurologic evaluation. Pediatr Neurol. 1996;14(3):203–10.PubMedGoogle Scholar
  68. 68.
    Morten KJ, et al. Liver mtDNA content increases during development: a comparison of methods and the importance of age- and tissue-specific controls for the diagnosis of mtDNA depletion. Mitochondrion. 2007;7(6):386–95.PubMedGoogle Scholar
  69. 69.
    Tiao MM, et al. Early stage of biliary atresia is associated with significant changes in 8-hydroxydeoxyguanosine and mitochondrial copy number. J Pediatr Gastroenterol Nutr. 2007;45(3):329–34.PubMedGoogle Scholar
  70. 70.
    Xing J, et al. Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst. 2008;100(15):1104–12.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Yu M, et al. Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life. 2007;59(7):450–7.PubMedGoogle Scholar
  72. 72.
    Saretzki G. Telomerase, mitochondria and oxidative stress. Exp Gerontol. 2009;44(8):485–92.PubMedGoogle Scholar
  73. 73.
    Kim JH, et al. The relationship between leukocyte mitochondrial DNA copy number and telomere length in community-dwelling elderly women. PLoS One. 2013;8(6):e67227.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Tyrka AR, et al. Association of telomere length and mitochondrial DNA copy number in a community sample of healthy adults. Exp Gerontol. 2015;66:17–20.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Pieters N, et al. Molecular responses in the telomere-mitochondrial axis of ageing in the elderly: a candidate gene approach. Mech Ageing Dev. 2015;145:51–7.PubMedGoogle Scholar
  76. 76.
    Tyrka AR, et al. Alterations of mitochondrial DNA copy number and telomere length with early adversity and psychopathology. Biol Psychiatry. 2016;79(2):78–86.PubMedGoogle Scholar
  77. 77.
    Hough CM, et al. Leukocyte telomere length predicts SSRI response in major depressive disorder: a preliminary report. Mol Neuropsychiatry. 2016;2(2):88–96.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Schutte NS, Malouff JM. A meta-analytic review of the effects of mindfulness meditation on telomerase activity. Psychoneuroendocrinology. 2014;42:45–8.PubMedGoogle Scholar
  79. 79.
    Kornfeld DS. Consultation-liaison psychiatry: contributions to medical practice. Am J Psychiatry. 2002;159(12):1964–72.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Massimo Biondi
    • 1
  • Francesco Saverio Bersani
    • 1
  • Massimo Pasquini
    • 1
  1. 1.Department of Human NeurosciencesSapienza University of RomeRomeItaly

Personalised recommendations